Clinical Trials Logo

Clinical Trial Summary

Specific Aim: To investigate if isotretinoin (13-cis-retinoic acid) administration decreases CYP2D6 activity in adolescent patients.


Clinical Trial Description

In this aim, we will conduct a drug-drug interaction study evaluating the effects of 13-cis-retinoic acid on non-induced CYP2D6 activity in adolescent patients. Secondary analysis will evaluate the relationship between retinoid concentrations and CYP2D6 activity in these special populations ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03076021
Study type Interventional
Source University of Washington
Contact
Status Completed
Phase Phase 4
Start date July 26, 2016
Completion date November 27, 2023

See also
  Status Clinical Trial Phase
Recruiting NCT04228315 - Biomarkers of P. Vivax Relapse N/A
Completed NCT01075802 - Study of Tamoxifen Dose Escalation in Breast Cancer Patients With CYP2D6 Polymorphisms N/A
Completed NCT03117660 - Effects of Retinoids on CYP2D6 Activity During Pregnancy Phase 1
Completed NCT03411759 - Cytochrome P450's Pharmacogenomics in Chronic Pain Patients
Completed NCT02428660 - Drug & Gene Interaction Risk Analysis With & Without Genetic Testing Among Patients Undergoing MTM N/A
Enrolling by invitation NCT03137368 - A Study to Evaluate Exemestane Tablets Combined With Ovarian Function Suppression/Ablation in Treatment of Premenopausal Breast Cancer Patients With CYP2D6*10 Mutations (STEP) Phase 3
Completed NCT02664350 - Precision Medicine Guided Treatment for Cancer Pain N/A